taldefgrobep alfa + Placebo + taldefgrobep alfa
Phase 3Active 0 watching 0 views this week📈 Rising
72
Development Stage
✓
Pre-clinical✓
Phase 1✓
Phase 24
Phase 35
ApprovedIndication / Disease
Spinal Muscular Atrophy
Conditions
Spinal Muscular Atrophy, Neuromuscular Diseases, SMA
Trial Timeline
Jul 6, 2022 → Jun 1, 2026
NCT ID
NCT05337553About taldefgrobep alfa + Placebo + taldefgrobep alfa
taldefgrobep alfa + Placebo + taldefgrobep alfa is a phase 3 stage product being developed by Biohaven for Spinal Muscular Atrophy. The current trial status is active. This product is registered under clinical trial identifier NCT05337553. Target conditions include Spinal Muscular Atrophy, Neuromuscular Diseases, SMA.
Hype Score Breakdown
Clinical
27
Activity
18
Company
5
Novelty
9
Community
10
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT05337553 | Phase 3 | Active |
Competing Products
20 competing products in Spinal Muscular Atrophy